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5o the Editor: An important side effect of several widely used
hemotherapeutic agents is cardiotoxicity and heart failure. Animal
odels demonstrate that granulocyte-colony stimulating factor (G-
SF) may offer cardioprotection against doxorubicin-induced cardio-
yopathy (1–3), but human data substantiating this are lacking.
To address this important issue, we conducted a retrospective
ohort study investigating the impact of G-CSF on left ventricular
jection fraction (EF) in oncology patients between 2007 and 2008 at
he University of Miami Miller School of Medicine. We evaluated
atients who received either cardiotoxic or noncardiotoxic chemother-
py and G-CSF to prevent chemotherapy-induced neutropenia.
ardiotoxic drugs included anthracyclines and trastuzumab. G-CSF
as administered daily 5 times after each chemotherapy cycle. We
ncluded patients who: 1) received G-CSF as a part of the treatment;
nd 2) had an echocardiogram before and after receiving at least 1
ose of G-CSF. For a control group, we evaluated patients who did
ot receive G-CSF but who had 2 echocardiograms. Only transtho-
acic echocardiograms were included. For this analysis, we selected the
owest reported EF determined by visual estimation. In addition,
ther echocardiographic parameters, notably systolic and diastolic
imensions, were collected.
The primary outcome was the effect of G-CSF on change in left
entricular EF between the baseline and follow-up echocardio-
ram. Secondary outcomes included the impact of G-CSF on left
entricular EF in patients receiving cardiotoxic chemotherapy
ompared with those who did not receive cardiotoxic drugs.
Baseline characteristics between the group that received G-CSF
nd the control group were analyzed using a t test for continuous
ariables and chi-square for categorical variables. For univariate
nalysis, we used a paired t test to compare the baseline and
Characteristics of the PatientsTable 1 Characteristics of the Patients
Control
(n 
Age, yrs 48
Female 40
Beta-blockers 46
ACEI 22
Hypertension 37.8
Diabetes mellitus 16.2
Cardiotoxic chemotherapy 9 (24
Filgrastim, mg (total) NA
ESV baseline 55.77
ESV follow-up 57.16
EDV baseline 105.11
EDV follow-up 118.85
Baseline EF 59.7
Days between echocardiograms 72
Values are mean  SD, %, or n (%).
ACEI  angiotensin-converting enzyme inhibitor; EDV  end-diastolic vo
granulocyte-colony stimulating factor; NA  not applicable.ollow-up EF between the G-CSF and control groups. Finally, we
erformed a multivariate linear regression analysis using the
hange in EF as a dependent variable to examine the impact of
-CSF, adjusting for demographics, use of beta-adrenergic an-
agonists or angiotensin-converting enzyme inhibitors (ACEI),
nd cardiotoxic drugs.
We included an interaction term to evaluate the association
etween G-CSF and the use of cardiotoxic drugs. Because a
ignificant interaction was found, we stratified the analysis by the
se of cardiotoxic drugs. Analyses were performed using STATA
ersion 10 (Stata Corp., College Station, Texas), and all signifi-
ance tests were 2-tailed.
Of a total of 597 patients admitted, 107 patients had 2
chocardiograms. Of these, 70 were in the G-CSF group, and 37
ere in the control group. In the G-CSF group, 28 (40%) patients
eceived cardiotoxic drugs, whereas in the control group, 9 (24%)
id so. Patients did not differ in age, sex, EF, use of beta-
drenergic antagonists or ACEI, days between echocardiograms,
nd baseline EF (Table 1).
Comparison of EF between baseline and follow-up echocar-
iograms revealed that in the G-CSF group, EF was preserved,
aving a baseline EF of 56.2  12.3%, and a follow-up EF of
5.8  10.1% (p  0.83). In contrast, in the control group, EF
ecreased from 59.7  6.4% at baseline to 55.2  9.6% at
ollow-up (p  0.02) (Fig. 1A).
Importantly, for patients who received cardiotoxic drugs, the
ffect of G-CSF was more pronounced. The G-CSF group had a
aseline EF of 59  10.5% and a follow-up EF of 57.6  4.9%
p 0.55); in contrast, in the control group, baseline mean EF was
8.3  6.6%, which decreased to 48.8  11.6% in follow-up
G-CSF Group
(n  70) p Value
44 14.9 0.19
43 0.70
49 0.70
16 0.46
25.71 0.26
14.28 0.78
28 (40%) 0.10
14,553 13,994 NA
7 40.96 20.24 0.01
4 44.21 24.45 0.01
0 98.32 31.66 0.28
8 100.96 36.47 0.01
56.2 12.3 0.11
70 88 0.91Group
37)
17.0
3
1
%)
30.5
23.7
29.4
21.2
6.4
98lume; EF  ejection fraction; ESV  end-systolic volume; G-CSF 
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January 25, 2011:516–9p  0.04) (Fig. 1B). The EF did not decline in patients not
xposed to cardiotoxic drugs.
End-systolic and end-diastolic volumes were not significantly
hanged in patients receiving G-CSF and cardiotoxic drugs (p 
.05). The analysis, adjusted for independent variables, including
ge, sex, use of beta-blockers, ACEI, and cardiotoxic drugs, found
significant beta coefficient of change in EF (beta: 5.22; 95%
onfidence interval [CI]: 0.56 to 9.8, p  0.02).
There are several mechanisms underlying a cardioprotective
ffect of G-CSF in patients receiving chemotherapy. First, G-CSF
obilizes bone marrow stem cells, at least in part by inducing
own-regulation of soluble derived factor (SDF)-1 and up-
egulation of its receptor, CXCR4 (4). Second, G-CSF may be
irectly cardioprotective in anthracycline models, reducing myo-
yte apoptosis by down-regulating the Fas protein (1) or by
estoring GATA-4 expression, which in turn enhances myocardial
xpression of MHC and troponin I. G-CSF receptor signaling can
Figure 1 The Impact of G-CSF on EF
The impact of granulocyte-colony stimulating factor (G-CSF) on ejection fraction
(EF) is shown in patients treated with all forms (A; n  107) and with cardio-
toxic (B; n  37) chemotherapy. As shown, EF fell in all patients not receiving
G-CSF (*p  0.02), and this decline was prevented by G-CSF. The magnitude
of decline was greater in patients receiving cardiotoxic chemotherapy and was
also fully prevented by G-CSF (†p  0.04).lso activate the Extracellular signal Regulated protein KinaseERK)/MAPK that is reduced in doxorubicin-induced cardiomy-
pathy and necessary for the activation of GATA-4 (2). Miyata et
l. (3) suggested that the mechanism of doxorubicin-induced
ardiomyopathy is fibrosis and autophagy, and G-CSF caused
ypertrophy of the cardiomyocytes via Jak/STAT signals, and
ecreased the fibrosis of the heart by overexpression of
etalloproteinase-2 and -9. Finally, Hamamoto et al. (5) demon-
trated that G-CSF enhanced proliferation of cardiomyocytes by
ctivating the G-CSF receptors present on the cardiomyocytes.
Currently, there are no randomized controlled trials that exam-
ne the efficacy of G-CSF to prevent doxorubicin-induced cardio-
yopathy. Our study suggests that the patients who received
-CSF with cardiotoxic chemotherapy experienced a preservation
f EF, unlike a control group in which EF fell. This effect cannot
e attributed to the chemotherapy, as a similar group not receiving
ardiotoxic chemotherapy also experienced a preserved EF during
reatment.
This study is limited as it employed echocardiographic evalua-
ion of left ventricular EF as opposed to the more accurate
echniques such as multigated acquisition (MUGA) scans or
agnetic resonance imaging. Furthermore, the interval between
chocardiograms was not uniform across all the patients. Doses of
-CSF were not the same in all patients, and the mobilization of
tem cells was not documented.
We conclude that patients receiving cardiotoxic chemotherapy
ight benefit from the use of G-CSF in order to reduce the chance
f developing chemotherapy-induced cardiomyopathy. The present
ndings strongly support the conduct of randomized controlled trials
o confirm this hypothesis.
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